WTX 212
Alternative Names: WTX-212; WTX-212ALatest Information Update: 23 Jul 2026
At a glance
- Originator Westlake Therapeutics
- Class Antineoplastics; Cell therapies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- No development reported Haematological malignancies
Most Recent Events
- 29 May 2026 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
- 22 Apr 2026 Pharmacokinetics data from a phase 0 trial in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research, 2026 (AACR-2026)
- 25 Nov 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in China (Parenteral) (NCT07269899)